Most-Read Oncology Articles of 2021
The most-read oncology news of 2021 included the FDA’s review of accelerated approvals, COVID-19 vaccine effectiveness in patients with blood cancer, and more.
Two Approvals in Urothelial Cancer Survive FDA Panel Scrutiny
As hearings of the FDA panel have shown, once a drug is approved and in clinical guidelines, pulling it from the market is not so simple, even if later trials do not confirm phase 2 results.
FDA Update: Merck Action on Keytruda Gastric Cancer Indication Tops Busy Week
Merck will withdraw Keytruda's advanced gastric indication after an FDA panel vote, a drug with supply problems gets a new indication, NDAs for an HIV therapy, and other news.
Antibodies Go Missing After COVID-19 Vaccination in Some Blood Cancer Patients
Lack of antibodies from vaccination mainly affects patients with B cell cancers. Experts say antibodies are just one piece of the puzzle and that other aspects of the immune system fend off serious cases of COVID-19.
Feasibility Study Shows Mobile Devices Help Patients Communicate Cancer Treatment Effects
Mobile devices for patients to report symptoms associated with immune checkpoint inhibitors address an unmet need.
ASCO 2021: Lumakras, First Approved KRAS-targeting Cancer Drug, Looks Promising
The FDA approved Amgen’s Lumakras (sotorasib) last week, the first drug targeting KRAS-mutated cancer to get the agency’s OK. But the clinical and commercial future of the drug is uncertain.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
